GABA.

The body builds its own GABA from glutamate using the enzyme glutamate decarboxylase, and that enzyme only works when vitamin B6's active form sits in it as the required cofactor. B6 therefore feeds the exact pathway that makes GABA, which is why the two belong together in a calming stack.

Magnesium works the other side of the same balance GABA does, providing the voltage block that quiets the excitatory NMDA glutamate channel while also modulating GABA-A receptor signaling. Alongside GABA it leans the nervous system toward its calmer, more settled state.

Valerian's valerenic acid modulates the same GABA-A receptors that GABA acts on, so both support winding down through one shared channel. Because they push in the same direction, their calming effects add together and drowsiness can compound.

L-theanine is a close chemical cousin of glutamate that gently dials down excitatory signaling and shifts brain activity toward a relaxed but alert, alpha-wave pattern. It has long been paired with GABA in calming formulas because both steer toward the same unhurried, settled state.

Glycine opens its own chloride channel in the brainstem and spinal cord, the same kind of inhibitory current GABA-A carries. The two raise inhibitory tone through separate receptors rather than competing for one.

Taurine binds GABA-A and glycine receptors as a low-potency agonist and also affects GABA transport. It adds to the same chloride conductance GABA acts on.

Apigenin is a flavone that occupies the benzodiazepine binding site and modulates how the GABA-A channel responds. It changes receptor sensitivity rather than adding more transmitter.

Chamomile's calming flavone content is largely apigenin and its glycosides, which act at the benzodiazepine site of GABA-A. It shifts receptor response while GABA supplies the ligand side.

Passionflower flavonoids modulate GABA-A currents and its extracts also affect GABA uptake. That is receptor-side action alongside the transmitter itself.

The biphenyl lignans in magnolia bark act as positive modulators at GABA-A subunits. They alter channel behaviour while GABA occupies the transmitter site.

Honokiol enhances GABA-evoked chloride current at the receptor rather than acting as a transmitter itself. Its effect depends on GABA being present.

Kavalactones increase GABA-A binding density and modulate the channel, alongside effects on sodium and calcium channels. The receptor-level action overlaps directly with GABA.

Rosmarinic acid and related constituents inhibit GABA transaminase, the enzyme that degrades GABA. Less breakdown means whatever GABA is present persists longer.

Glutamine is converted to glutamate in neurons, and glutamate decarboxylase then makes GABA from it. Glutamine sits two steps upstream of the transmitter itself.

Melatonin acts on MT1 and MT2 receptors to signal biological night, which is timing rather than inhibitory tone. The two levers are different parts of settling down.

Picamilon is GABA joined to niacin, a pairing that crosses membranes more readily and then splits to release GABA and nicotinic acid. It is a delivery form of the same transmitter, not a second mechanism.

Endogenous GABA is made in one step, when glutamate decarboxylase removes a carboxyl group from glutamate, and that enzyme cannot work without pyridoxal-5-phosphate sitting in its active site. Supplying the already-phosphorylated form of B6 puts the cofactor in place without the liver conversion step pyridoxine needs. This is about the body's own GABA synthesis, not about absorption of swallowed GABA.

GABA is not only a supplement ingredient, it is a normal fermentation product of several Lactobacillus and Bifidobacterium species that carry the same decarboxylase humans use. In a randomised, double-blind, placebo-controlled trial a Lactiplantibacillus plantarum strain raised urinary GABA alongside self-reported sleep measures. Urinary GABA is a marker of production, not itself a sleep outcome.

Plantarum strains are among the better characterised GABA producers, using glutamate decarboxylase on glutamate present in the gut. The cited trial paired improved self-reported sleep with a rise in urinary GABA, which links the strain to the pathway rather than showing the GABA caused the sleep change. Formulas that pair the free amino acid with a producing strain are working two routes to the same molecule.

B. longum is a resident colonic genus with documented GABA-producing strains, so it can add to the luminal pool from dietary glutamate. Strain identity matters here, because production is strain-specific and not a property of the species as a whole. Culture and animal work support the pathway; human GABA output from a named strain is the part still thin.

GOS is fermented preferentially by bifidobacteria, so it shifts which organisms dominate the colon rather than adding GABA itself. Where the resident strains happen to be producers, more substrate means more of their metabolic output. The chain from prebiotic to measured GABA in a person has not been laid out end to end.

Inulin is not digested in the small intestine and arrives in the colon as fuel for the same genera that carry glutamate decarboxylase. That makes it a substrate-level partner for microbial GABA production rather than a direct source. Fermentable fibre also raises gas and bloating in some people at higher intakes.

Zinc sits at modulatory sites on GABA-A receptors and changes chloride current depending on the subunit composition, potentiating some assemblies and inhibiting others. That makes it a modulator of the receptor GABA acts on rather than an additive dose of the same signal. The direction of the effect is subunit-dependent, so no single claim covers all synapses.

Caffeine blocks adenosine receptors and increases arousal, the opposite direction to GABAergic inhibition, so the two pull against each other in the same product. Some nootropic blends do this on purpose, pairing a stimulant with a calming amino acid to blunt jitteriness. Worth flagging plainly rather than filing as a benefit, since the net effect depends entirely on the doses chosen.

Tryptophan feeds serotonin and downstream melatonin synthesis, a different route to evening calm than direct GABAergic signalling. The pairing is a formulation pattern with mechanistic logic on each side, not a tested combination with its own trial. Additive drowsiness is the realistic outcome to plan around.

5-HTP bypasses the rate-limiting hydroxylation step and raises serotonin availability, which is a distinct mechanism from GABA receptor signalling. Products combine them for evening use on that separate-pathway logic. Combined sedative load is the practical consideration, and the combination itself has not been trialled as a unit.

GABA has been given with whey protein around resistance training in small human studies looking at growth hormone response and lean mass. Growth hormone is a marker, and the trials are small, so this belongs in the promising column rather than the established one. The protein contributes the amino acids; the GABA is being tested for the hormonal signal.